ProMetic Life Sciences

ProMetic’s PBI-4050 IPF phase II trial shows positive results

Friday, November 18, 2016

ProMetic Life Sciences has announced positive interim results from its open label phase II clinical trial in patients suffering from idiopathic pulmonary fibrosis (IPF). In addition to demonstrating that PBI-4050 is safe and well-tolerated in patients suffering from IPF, the objective of this study was to provide early evidence of clinical benefits of PBI-4050 treatment whether used alone or in addition to either nintedanib or pirfenidone. Forty patients are enrolled in the study in 6 sites across Canada. At this time, the corporation is reporting on the first 30 patients that have completed their 12 weeks of treatment.

[Read More]